urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin Kidney J 2016; 9 (3):444–453.
164 [164] Bischoff A, Bucher M, Gekle M, Sauvant C. PAH clearance after renal ischemia and reperfusion is a function of impaired expression of basolateral Oat1 and Oat3. Physiol Rep 2014; 2 (2):e00243.
165 [165] Lowenstein J, Grantham JJ. The rebirth of interest in renal tubular function. Am J Physiol Renal Physiol 2016; 310 (11):F1351–F1355.
166 [166] Schneider R, Meusel M, Betz B, Held C, Möller‐Ehrlich K, Büttner‐Herold M, Wanner C, Gekle M, Sauvant C. Oat1/3 restoration protects against renal damage after ischemic AKI. Am J Physiol Renal Physiol 2015; 308 (3):F198–F208.
167 [167] Saigo C, Nomura Y, Yamamoto Y, Sagata M, Matsunaga R, Jono H, Nishi K, Saito H. Meclofenamate elicits a nephropreventing effect in a rat model of ischemic acute kidney injury by suppressing indoxyl sulfate production and restoring renal organic anion transporters. Drug Des Devel Ther 2014; 8:1073–1082.
168 [168] Saito H, Yoshimura M, Saigo C, Komori M, Nomura Y, Yamamoto Y, Sagata M, Wakida A, Chuman E, Nishi K, Jono H. Hepatic sulfotransferase as a nephropreventing target by suppression of the uremic toxin indoxyl sulfate accumulation in ischemic acute kidney injury. Toxicol Sci 2014; 141 (1):206–217.
169 [169] Bischoff A, Bucher M, Gekle M, Sauvant C. Differential effect of COX1 and COX2 inhibitors on renal outcomes following ischemic acute kidney injury. Am J Nephrol 2014; 40 (1):1–11.
170 [170] Preising C, Schneider R, Bucher M, Gekle M, Sauvant C. Regulation of expression of renal organic anion transporters OAT1 and OAT3 in a model of ischemia/reperfusion injury. Cell Physiol Biochem 2015; 37 (1):1–13.
171 [171] Pannu N, Nadim MK. An overview of drug‐induced acute kidney injury. Crit Care Med 2008; 36 (4 Suppl):S216–S223.
172 [172] Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31 (4):971–997.
173 [173] Guo X, Meng Q, Liu Q, Wang C, Sun H, Peng J, Ma X, Kaku T, Liu K. JBP485 improves gentamicin‐induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats. Toxicol Appl Pharmacol 2013; 271 (2):285–295.
174 [174] Jia Y, Liu Z, Wang C, Meng Q, Huo X, Liu Q, Sun H, Sun P, Yang X, Ma X, Liu K. P‐gp, MRP2 and OAT1/OAT3 mediate the drug‐drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol 2016; 306:27–35.
175 [175] Schwenk MH, Pai AB. Drug transporter function‐‐implications in CKD. Adv Chronic Kidney Dis 2016; 23 (2):76–81.
176 [176] Huo X, Liu K. Renal organic anion transporters in drug‐drug interactions and diseases. Eur J Pharm Sci 2018; 112:8–19.
177 [177] Masereeuw R, Mutsaers HA, Toyohara T, Abe T, Jhawar S, Sweet DH, Lowenstein J. The kidney and uremic toxin removal: glomerulus or tubule? Semin Nephrol 2014; 34 (2):191–208.
178 [178] Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM. Reduced renal clearance of cefotaxime in asians with a low‐frequency polymorphism of OAT3 (SLC22A8), J Pharm Sci 2013; 102 (9):3451–3457.
179 [179] Lozano E, Briz O, Macias RI, Serrano MA, Marin JJ, Herraez E. Genetic heterogeneity of SLC22 family of transporters in drug disposition. J Pers Med 2018; 8 (2):14.
180 [180] Sakurai Y, Motohashi H, Ogasawara K, Terada T, Masuda S, Katsura T, Mori N, Matsuura M, Doi T, Fukatsu A, Inui K. Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm Res 2005; 22 (12):2016–2022.
181 [181] Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G. Profiling of drug‐metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab‐Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J 2012; 13 (4):335–341.
182 [182] Engstrom K, Ameer S, Bernaudat L, Drasch G, Baeuml J, Skerfving S, Bose‐O'Reilly S, Broberg K. Polymorphisms in genes encoding potential mercury transporters and urine mercury concentrations in populations exposed to mercury vapor from gold mining. Environ Health Perspect 2012; 121 (1):85–91.
183 [183] Sun CY, Wu MS, Lee CC, Chen SH, Lo KC, Chen YH. A novel SNP in the 5′ regulatory region of organic anion transporter 1 is associated with chronic kidney disease. Sci Rep 2018; 8 (1):8085.
184 [184] Cho SK, Kim S, Chung JY, Jee SH. Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ Open 2015; 5 (11):e009360.
185 [185] Urquhart BL, Kim RB. Blood‐brain barrier transporters and response to CNS‐active drugs. Eur J Clin Pharmacol 2009; 65 (11):1063–1070.
186 [186] Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y. Limited brain distribution of [3R,4R,5S]‐4‐acetamido‐5‐amino‐3‐(1‐ethylpropoxy)‐1‐cyclohexene‐1‐carboxyl ate phosphate (Ro 64‐0802), a pharmacologically active form of oseltamivir, by active efflux across the blood‐brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance‐associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 2009; 37 (2):315–321.
187 [187] Miyajima M, Kusuhara H, Fujishima M, Adachi Y, Sugiyama Y. Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood‐brain barrier in mice. Drug Metab Dispos 2011; 39 (5):814–819.
188 [188] Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43 (8):487–514.
189 [189] Zhou F, Illsley NP, You G. Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells. Eur J Pharm Sci 2006; 27 (5):518–523.
190 [190] Schnabolk GW, Youngblood GL, Sweet DH. Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am J Physiol Renal Physiol 2006; 291 (2):F314–F321.
191 [191] Li W, Mei X, Tu YY. Effects of tea polyphenols and their polymers on MAPK signaling pathways in cancer research. Mini Rev Med Chem 2012; 12 (2):120–126.
192 [192] Taleb O, Maammar M, Brumaru D, Bourguignon JJ, Schmitt M, Klein C, Kemmel V, Maitre M, Mensah‐Nyagan AG. Xanthurenic acid binds to neuronal G‐protein‐coupled receptors that secondarily activate cationic channels in the cell line NCB‐20. PLoS One 2012; 7 (11):e48553.
193 [193] Jansen J, Jansen K, Neven E, Poesen R, Othman A, van Mil A, Sluijter J, Sastre Torano J, Zaal EA, Berkers CR, Esser D, Wichers HJ, van Ede K, van Duursen M, Burtey S, Verhaar MC, Meijers B, Masereeuw R. Remote sensing and signaling in kidney proximal tubules stimulates gut microbiome‐derived organic anion secretion. Proc Natl Acad Sci U S A 2019; 116 (32):16105–16110.
194 [194] Duan P, Li S, You G. Regulation of human organic anion transporter 4 by parathyroid hormone‐related protein and protein kinase A. Int J Biochem Mol Biol 2012; 3 (3):322–327.
195 [195] Phatchawan A, Chutima S, Varanuj C, Anusorn L. Decreased renal organic anion transporter 3 expression in type 1 diabetic rats. Am J Med Sci 2014; 347 (3):221–227.
196 [196] Rosenthal SB, Bush KT, Nigam SK. A network of SLC and ABC transporter and DME genes involved in remote sensing and signaling in the gut‐liver‐kidney axis. Sci Rep 2019; 9 (1):1–19.
197 [197] Chahine S, Campos A, O'Donnell MJ. Genetic knockdown of a single organic anion transporter alters the expression of functionally related genes in Malpighian tubules of Drosophila melanogaster. J Exp Biol 2012; 215 (Pt 15):2601–2610.
198 [198] Chahine S, Seabrooke S, O'Donnell MJ. Effects of genetic knock‐down of organic anion transporter genes on secretion of fluorescent organic ions by Malpighian tubules of Drosophila melanogaster. Arch Insect Biochem Physiol 2012; 81 (4):228–240.
199 [199] Masereeuw